Loading…
← CockpitCompetitor Analysis › 688520.SS Sinocelltech Group Limited Class AOpen in the cockpit ↗

Sinocelltech Group Limited Class A688520.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese biopharma developing recombinant protein and antibody drugs; specific product line not fully established from available knowledge.

Momentum laggard 15
Mkt cap
$1.90B
US dollars, full cap
Free float
10%
of shares outstanding
$/day
$8.93M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-30.6 pp
WACC 8.5%
Hurdle
n/a
no reverse DCF
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥27.32
1D-1.7%
1W-12.7%
1M-18.0%
3M-31.1%
6M-35.1%
YTD-36.9%
1Y-46.7%
ATR %4.8%
52w lowhigh48.8% off high

What Sinocelltech does

Chinese biopharma developing recombinant protein and antibody drugs; specific product line not fully established from available knowledge.

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals

Moat: none

Headquarters: Beijing, China · Employees: 2,200

Sinocelltech at a glance

Size Sinocelltech (688520.SS) is a China Health Care company (Biotechnology) with a market value of $1.90B, the 1220th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥27.32 on 18 Nov 2026.

Performance Over six months the shares fell 35.1%, against -3.6% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue fell 39.6% over the last twelve months (peer median +13.7%); the operating margin is -75.0% (peer median -29.7%).

Valuation It trades at 13.6× enterprise value to sales against a peer median of 13.2× (8th cheapest of 15).

Capital Return on invested capital runs 30.6 points below its cost of capital (8.5% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 97688520.SS 66
Six months, rebased to 100: Sinocelltech against the median of its 20 peers (local-currency closes).

Sinocelltech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.14BCN¥1.55BCN¥2.50BCN¥1.88BCN¥1.02B
Revenue growth—-38%+33%+85%—
Gross profitCN¥1.05BCN¥1.30BCN¥2.25BCN¥1.72BCN¥924M
EBITDAn/a-CN¥259MCN¥758MCN¥164M-CN¥239M
Net income-CN¥958M-CN¥565MCN¥112M-CN¥396M-CN¥519M
Free cash flow-CN¥555M-CN¥490M-CN¥248M-CN¥886M-CN¥976M
Capital expenditureCN¥193MCN¥217MCN¥376MCN¥505MCN¥555M
Total debtCN¥3.62BCN¥3.90BCN¥3.15BCN¥2.75BCN¥2.30B

Quarterly statements and history in the cockpit →

Sinocelltech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%MRVITRVIBCRXREPLSEPNTRAX300601VERACOAGZBIORXRXSTOKALMR688520.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Sinocelltech is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%+300%0×50×100×150×MRVIBCRXSEPN300601ZBIORXRXSTOKALMR300676688520.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sinocelltech is the large dot.

Sinocelltech competitors and peer comparison

How Sinocelltech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sinocelltech against its 20 peers (data as of 18 Nov 2026)
Measure688520.SSPeer medianRank in peer set
1-month return-18.0%-1.1%3rd lowest of 20
6-month return-35.1%-3.6%lowest of 19
Distance from 52-week high-48.8%-33.4%3rd lowest of 21
Revenue growth (TTM)-39.6%+13.7%4th lowest of 15
Operating margin-75.0%-29.7%7th lowest of 15
EV / Sales13.6×13.2×8th cheapest of 15
ROIC minus cost of capital-30.6 pp-8.6 pp2nd lowest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%

Questions

Which companies are Sinocelltech's closest peers?
The cockpit's peer set: Maravai Lifesciences (MRVI), Trevi Therapeutics (TRVI), BioCryst Pharmaceuticals (BCRX), Replimune (REPL), Septerna (SEPN), First Tracks Biotherapeutics (TRAX), Shenzhen Kangtai Biological Products (300601.SZ), Vera Therapeutics (VERA).
Is Sinocelltech expensive compared with its peers?
On ev / sales it trades at 13.6× against a peer median of 13.2×, 8th cheapest of 15 in its peer set.
How has Sinocelltech stock performed?
Over six months to 18 Nov 2026 the shares returned -35.1% against -3.6% for the median peer; over one year -46.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.